Sun Pharma Up Over 2% As Its Subsidiary Gets Nod For Generic Zetia Tablets


Sun Pharma’s wholly-owned subsidiary has received final approval from USFDA for Abbreviated New Drug Application (ANDA) for generic version of Zetia®, (ezetimibe) Tablets 10mg, the company informed the bourses on Tuesday.

These generic ezetimibe tablets are therapeutic equivalents of Merck’s Zetia® tablets, according to a BSE filing.

Meanwhile, Sun Pharma was up by 2.3% at Rs 545.85 per share at 0925 hours IST on BSE. It hit a high of Rs 551.40 and a low of Rs 545 in the morning session on Tuesday.

The stock has underperformed both BSE Sensex and BSE Healthcare over a period of one year. Its peers are Lupin and Cadila Healthcare.

Sun Pharmaceutical Industries Limited’s business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API).

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: